Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ORMP | ORAMED PHARMACEUTICALS INC. | 2026-10-15 14:05:31 | 4.17 | 0.02 | 0.48 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORMP | 0001176309 | ORAMED PHARMACEUTICALS INC. | US68403P2039 | 5299006K52ZIIGQJ6R84 | 980376008 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR | NEW YORK | NY | 10036 | UNITED STATES | US | 646-844-1164 | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036 | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036 | Integrated Security Technologies, Inc. | Biotech | 2006 | Nadav Kidron | — | http://oramed.com | 77,659,391 | 41,314,211 | 41,597,354 | Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange. | 2026-10-09 04:20:48 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 77,659,391 | -53,531,216 | -40.8042 | 40,446,179 | -404,276 | -0.9896 |
| 2024 | 131,190,607 | 665,085 | 0.5095 | 40,850,455 | 331,295 | 0.8176 |
| 2023 | 130,525,522 | -39,068,827 | -23.0366 | 40,519,160 | 735,347 | 1.8484 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Dr. Miriam Kidron | Director, Chief Scientific Officer | 2025 | 439,902 | 271,994 | — | — | 48,455 | 2,166,384 |
| Nadav Kidron | Chairman, Chief Executive Officer, President | 2025 | 619,529 | 379,935 | — | — | 65,927 | 4,774,460 |
| Dr. Miriam Kidron | Director, Chief Scientific Officer | 2024 | 408,104 | 155,291 | — | — | 19,607 | 1,534,547 |
| Nadav Kidron | Chairman, Chief Executive Officer, President | 2024 | 540,145 | 270,767 | — | — | 62,017 | 2,097,689 |
| Nadav Kidron | Chief Executive Officer, President, Chairman | 2023 | 462,988 | 242,576 | — | — | 48,738 | 1,659,222 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 2,000,000 | — | 1,340,000 |
| Cost Of Revenue | 1,987,000 | — | — |
| Gross Profit | 13,000 | — | — |
| Research And Development Expenses | 6,381,000 | 6,324,000 | 8,971,000 |
| General And Administrative Expenses | 8,720,000 | 6,457,000 | 8,425,000 |
| Operating Expenses | 15,101,000 | — | — |
| Operating Income | -15,088,000 | -12,781,000 | -15,769,000 |
| Net Income | 64,050,000 | -19,103,000 | 5,525,000 |
| Earnings Per Share Basic | 1.53 | -0.48 | 0.14 |
| Earnings Per Share Diluted | 1.5 | -0.48 | 0.14 |
| Weighted Average Shares Outstanding Basic | 41,402,997 | 40,828,380 | 40,315,068 |
| Weighted Average Shares Outstanding Diluted | 42,418,644 | 40,828,380 | 40,566,901 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 45,947,000 | 54,420,000 | 9,055,000 |
| Marketable Securities Current | 5,417,000 | 3,441,000 | — |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 2,741,000 | 1,291,000 | 537,000 |
| Total Assets Current | 133,271,000 | 143,221,000 | 162,584,000 |
| Marketable Securities Non Current | 8,371,000 | — | 1,807,000 |
| Property Plant And Equipment | 586,000 | 698,000 | 873,000 |
| Other Assets Non Current | 44,000 | 32,000 | — |
| Total Assets Non Current | 97,593,000 | 12,057,000 | 57,967,000 |
| Total Assets | 230,864,000 | 155,278,000 | 220,551,000 |
| Accounts Payable | 443,000 | 789,000 | 551,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | 51,013,000 |
| Other Liabilities Current | 1,712,000 | 59,000 | 59,000 |
| Total Liabilities Current | 19,086,000 | 5,685,000 | 53,214,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | 60,000 | — |
| Total Liabilities Non Current | 12,034,000 | 4,246,000 | 4,444,000 |
| Total Liabilities | 31,120,000 | 9,013,000 | 56,730,000 |
| Common Stock | 472,000 | 480,000 | 485,000 |
| Retained Earnings | -123,436,000 | -176,616,000 | -157,556,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 199,744,000 | 146,265,000 | 163,821,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 121,000 | 193,000 | 196,000 |
| Share Based Compensation Expense | 5,992,000 | 4,053,000 | 4,212,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 998,000 | 356,000 | -852,000 |
| Change In Accounts Payable | 1,130,000 | 3,525,000 | -2,225,000 |
| Change In Other Liabilities | -60,000 | 2,000 | 7,000 |
| Cash From Operating Activities | -9,145,000 | -8,412,000 | -10,295,000 |
| Purchases Of Marketable Securities | 9,846,000 | 1,307,000 | 91,369,000 |
| Sales Of Marketable Securities | 39,566,000 | 64,500,000 | 109,760,000 |
| Acquisition Of Property Plant And Equipment | 9,000 | 18,000 | 254,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | 1,924,000 | — | 99,550,000 |
| Cash From Investing Activities | 5,443,000 | 105,817,000 | -73,038,000 |
| Tax Withholding For Share Based Compensation | — | 2,000 | — |
| Payments Of Dividends | 10,870,000 | — | — |
| Issuance Of Common Stock | 5,992,000 | — | 2,428,000 |
| Repurchase Of Common Stock | 2,155,000 | 2,484,000 | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | 49,550,000 | 50,000,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -4,741,000 | -52,036,000 | 51,978,000 |
| Change In Cash | -8,473,000 | 45,365,000 | -31,409,000 |
| Cash At End Of Period | 45,947,000 | 54,420,000 | 9,055,000 |
| Income Taxes Paid | 3,318,000 | — | — |
| Interest Paid | — | 2,316,000 | 574,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 1.53 | -0.48 | 0.14 |
| Price To Earnings Ratio | 1.8627 | -5.0417 | 16.5 |
| Earnings Growth Rate | -418.75 | -442.8571 | -85.1064 |
| Price Earnings To Growth Ratio | -0.0044 | 0.0114 | -0.1939 |
| Book Value Per Share | 4.8244 | 3.5824 | 4.0635 |
| Price To Book Ratio | 0.5907 | 0.6755 | 0.5685 |
| Ebitda | 67,489,000 | -16,323,000 | 7,758,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | 0.0921 | — | — |
| Dividend Payout Ratio | 0.1697 | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 9,000 | 18,000 | 254,000 |
| Free Cash Flow | -9,154,000 | -8,430,000 | -10,549,000 |
| Return On Equity | 0.3207 | -0.1306 | 0.0337 |
| One Year Beta | 0.5513 | 0.8615 | 0.511 |
| Three Year Beta | 0.6019 | 1.4232 | 1.5531 |
| Five Year Beta | 1.2166 | 0.9591 | 0.9233 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Hexter Joshua | COO & CBO | 2026-10-01 | 30,000 | D | 1,328,130 |
| Gabay Avraham | Chief Financial Officer | 2026-10-01 | 20,000 | D | 861,076 |
| Hexter Joshua | COO & CBO | 2026-07-02 | 50,000 | A | 1,073,384 |
| Hexter Joshua | COO & CBO | 2026-07-02 | 50,000 | D | 50,000 |
| Gabay Avraham | Chief Financial Officer | 2026-07-01 | 73,360 | D | 671,785 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Brad Knott | 2025-02-25 | NC13 | Sale | 2025-01-10 | — | $15,001 - $50,000 |
| Andrew Garbarino | 2022-01-14 | NY02 | Sale | 2022-01-14 | — | $1,001 - $15,000 |
| Andrew Garbarino | 2021-11-03 | NY02 | Sale (Partial) | 2021-10-01 | — | $1,001 - $15,000 |
| Andrew Garbarino | 2021-05-24 | NY02 | Purchase | 2021-04-23 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| BAILARD, INC. | 2026-09-30 | 151,672 | 32,478 | 4.67 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 2026-09-30 | 67,376 | 16,042 | 4.2 |
| Farther Finance Advisors, LLC | 2026-09-30 | 2,270 | 486 | 4.6708 |
| GAMMA Investing LLC | 2026-09-30 | 859 | 184 | 4.6685 |
| STATE STREET CORP | 2026-06-30 | 1,164,501 | 242,100 | 4.81 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Extended Market Index Fund | USMIX | 3,654 | 14,871.78 | 0.0018 |
| Global X Funds | 2026-07-31 | Global X Russell 2000 ETF | RSSL | 16,237 | 66,084.59 | 0.0044 |
| PRINCIPAL FUNDS, INC. | 2026-07-31 | R-6 | PSMVX | 2,771 | 11,277.97 | 0.0009 |
| PRINCIPAL FUNDS, INC. | 2026-07-31 | Class J | PSMJX | 2,771 | 11,277.97 | 0.0009 |
| PRINCIPAL FUNDS, INC. | 2026-07-31 | Institutional Class | PPVIX | 2,771 | 11,277.97 | 0.0009 |